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Abstract: Background: Faecal microbiome transplantation (FMT) appears to be an effective method
for treating irritable bowel syndrome (IBS) patients. However, it is not clear if a high transplant dose
and/or repeating FMT are/is needed to ensure a response. The present study was undertaken to
clarify this matter. Methods: Ten IBS patients who did not respond to a 30-g transplant subsequently
received a 60-g transplant into the duodenum via a gastroscope. The patients provided faecal samples
before and 1 month after FMT. They completed five questionnaires measuring symptoms, fatigue and
quality of life at baseline and then at 2 weeks, 1 month and 3 months after FMT. The dysbiosis index
(DI) was measured using the GA-map Dysbiosis Test®. Results: Seven patients (70%) responded to
the 60-g transplant, with significant clinical improvements in the abdominal symptoms, fatigue and
quality of life in 57%, 80% and 67% of these patients. The 60-g transplant also reduced the DI.
Conclusion: FMT is an effective treatment for IBS. A high-dose transplant and/or repeated FMT
increase the response rate and the intensity of the effects of FMT.
Keywords: abdominal symptoms; dysbiosis; faecal microbiota transplantation; fatigue; IBS; quality
of life
1. Introduction
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder affecting 12.1% of the world
population [1,2]. There are no biochemical or radiological tests for the diagnosis of IBS, and the diagnosis
of IBS is based on symptom criteria such as the Rome criteria [3]. IBS affects the patients’ quality of life
in the same degree as major chronic diseases such as diabetes, liver and kidney failure [3]. There is no
effective treatment for the condition, and the current treatment in the clinic is symptomatic [3].
The aetiology of IBS appears to involve multiple factors, including genetics, environment,
social learning, dietary intake, intestinal microbiota, low-grade inflammation and disturbances in the
endocrine cells of the gastrointestinal tract [1]. The intestinal bacterial composition differs between
IBS patients and healthy subjects [4–17]. The role of the intestinal microbiome in several diseases and
disorders including IBS has received considerable attention recently [15–18]. The composition and
proportions of microbial fractions in healthy subjects are affected by several factors, including genetic
factors, diet, social behaviours and other environmental factors [18]. The ideal microbiome composition
and bacteria species that are important in the pathophysiology of IBS remain unclear [15,18,19].
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Moreover, the impact of low diversity of intestinal bacteria (dysbiosis) in IBS patients is still
debated [16–18].
Faecal microbiome transplantation (FMT) has been performed in patients with IBS with the aim
of restoring their intestinal microbiota to a healthy condition [18,20,21]. Applying FMT to a small
cohort of IBS patients in open-label studies produced positive results [18,20,21]. However, conflicting
results have been reported for two recently published randomised double-blind placebo-controlled
studies [22,23].
The outcome of FMT seems to be donor-dependent, and the utilization of a so-called superdonor
appears to be essential for successful FMT [24]. A superdonor has been defined as a healthy subject
who is normobiotic and has a favourable bacterial signature [24]. We recently conducted a randomised,
double-blind placebo-controlled study using a single superdonor, and found that the response rate was
higher and the effect was stronger in patients who received 60-g transplants than in those who received
30-g transplants [25]. The present study was conducted to establish whether the non-responders to a
30-g transplant in the previous study would respond to a 60-g transplant.
2. Material and Methods
2.1. Study Design
Patients who did not respond to a 30-g transplant in the previous randomised double-blind
placebo-controlled study were enrolled in the present open-label study to receive a 60-g transplant.
The patients provided a faecal sample at the baseline and completed five questionnaires to measure
their symptoms, fatigue and quality of life. The patients provided another faecal sample at 1 month
after FMT, and they completed a further set of questionnaires at 2 weeks, 1 month and 3 months
after FMT, which were sent by post. Polyethylene glycol and loperamide were allowed during the
intervention as rescue medication.
2.2. The Donor
The donor used has been described in detail elsewhere [25]. In summary, he was a 36-year-old
male with a body mass index (BMI) of 23.5 kg/m2. He was non-smoker and did not take any medication.
He was born by vaginal delivery and breastfed. He was screened according to the standard guidelines
for FMT donors [26]. In summary, he was interviewed and his medical history and lifestyle habits were
reviewed to exclude any exposure to infectious agents or risky social or sexual behaviour such as drug
or alcohol abuse. In addition, gastrointestinal, metabolic, and neurological disorders were excluded
through physical examination and blood tests. He had also undergone serological tests and stool
cultures/examinations in order to avoid any risk of transmitting an infectious disease to the recipients.
The donor regularly consumed dietary supplements rich in protein, vitamins, fibre and minerals.
Before using his faeces, an analysis of his faecal bacteria showed a dysbiosis index (DI) of 1, indicating
normobiosis. The donor bacterial profile deviated from the normal abundance in 14 out of the
39 bacteria markers tested. Twelve of the deviating bacteria belonged to phylum Firmicutes, one in
the phylum Proteobacteria and one in the phylum Verrucomicrobia. Of the bacteria belonging to the
Firmicutes phylum, Lactobacillus, Streptococcus and Dorea spp. were higher than the normal levels.
2.3. Patients
Ten IBS patients who did not respond to a 30-g transplant in the previous study [24] were included
in the present study, and received a 60-g transplant at 3–4 months after the first transplant. They had IBS
according to the Rome IV criteria without alarming symptoms. The medical history was obtained for
all of the patients, and they were examined physically. In addition, they were examined by gastroscopy
and colonoscopy to exclude other gastrointestinal diseases. All of the patients adhered to a modified
NICE (National Institute for Health and Care Excellence) diet. They comprised eight females and two
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males aged 39.1 ± 9.0 years (mean ± SD), and three of them had diarrhoea-dominated IBS (IBS-D),
two had constipation-dominated IBS (IBS-C) and five had mixed IBS (IBS-M).
2.4. Collection, Preparation and Administration of Faecal Samples
All faecal samples were frozen immediately and kept at −20 ◦C until they were delivered frozen
to hospital on the same day, where they were kept at −80 ◦C. The faecal samples of the donor were
thawed at 4 ◦C for 2 days before FMT. On the day of the FMT, the faecal samples were weighed,
and each 30 g of the faeces was mixed with 40 mL of sterile saline, filtered through a 110 × 10 cm
non-woven swab (One Med, Helsinki, Finland), drawn into 50-mL sterile syringes, sealed and kept
at 4 ◦C until the time of the FMT. To achieve a 60-g transplant, 80 mL of this solution was injected
through the working channel of a gastroscope into the distal duodenum. The working channel of the
gastroscope was then flushed with another 40 mL of sterile saline.
2.5. Questionnaires
Abdominal symptoms were assessed by the IBS Symptom Severity Score (IBS-SSS) and Birmingham
IBS symptom questionnaires [27,28]. Some of the items of these two questionnaires overlap, but they
were both completed since the IBS-SSS lacks items about diarrhoea and constipation, and the
Birmingham IBS symptom questionnaire does not contain an item about abdominal distension.
Fatigue was measured using the Fatigue Assessment Scale (FAS) [29]. Quality of life was measured by
the IBS Quality of Life (IBS-QoL) and the Short-Form Dyspepsia Index (SF-NDI) questionnaires [30–32].
These questionnaires are complementary since the SF-NDI contains a specific item about work/study
that the IBS-QoL questionnaire lacks. In contrast to the IBS-QoL, which measures the quality of life in
such a way that an increase in the score indicates an improvement in the quality of life, the SF-NDI
measures the reduction in the quality of life, with a decrease in the score indicating an improvement in
the quality of life.
A reduction of the total IBS-SSS of ≥50 points after the FMT was considered a response.
Furthermore, significant clinical improvements in abdominal symptoms, fatigue and quality of life were
considered to have occurred in patients with a decrease of ≥175 points in the total IBS-SSS, a decrease
of ≥4 points in the FAS score and an increase of ≥14 points in the IBS-QoL score, respectively [27,31,33].
2.6. Dysbiosis Index
The DI was measured using a commercially available test (GA-map Dysbiosis Test®, Genetic
Analysis, Oslo, Norway). The method has been described in detail elsewhere [34,35].
2.7. Ethics
This study was approved by the Regional Committee for Medical and Health Research Ethics
West, Bergen, Norway (approval no. 2017/1197/REK vest). All subjects provided oral and written
consent to participate. The study was registered at www.clinicaltrials.gov (NCT03822299).
2.8. Statistical Analysis
The paired t-test and Kruskal–Wallis test with Dunn’s multiple-comparisons test as a post-test
were used as applicable. A probability value of p < 0.05 was considered significant.
3. Results
Seven of the ten patients responded to the 60-g transplant (70%). The three non-responders
belonged to the IBS subtypes IBS-D (n = 1), IBS-C (n = 1) and IBS-M (n = 1).
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3.1. Questionnaires
The abdominal symptoms as assessed by the IBS-SSS and Birmingham IBS symptom questionnaires
were significantly reduced following the FMT with the 60-g transplant (Figure 1; Figure 2), as was
the fatigue score (Figure 3). The quality of life of the patients improved after they received the 60-g
transplant, as indicated by their scores for the IBS-QoL and SF-NDI questionnaires (Figures 4 and 5).
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Figure 1. The Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS) at different intervals after
receiving 30-g and 60-g transplants for the total score (A), abdominal pain (B), abdominal distension
(C), dissatisfaction with bowel habits (D) and interference with quality of life (E). * p < 0.05 compared
to baseline. FMT: faecal microbiome transplantation.
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abdominal pain (B), diarrhoea (C) and constipation (D). * p < 0.05; ** p < 0.01 compared to baseline.
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Figure 3. Fatigue as measured by the Fatigue Assessment Scale (FAS) questionnaire was reduced in IBS
patients after they received a 60-g transplant but not when they received a 30-g transplant. * p < 0.05;
** p < 0.01 compared to baseline.
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3.2. Dysbiosis Index
The DI decreased significantly following FMT with a 60-g transplant but not with a 30-g transplant
(Figure 6).
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4. Discussion
As mentioned previously, the intestinal bacterial profile of IBS patients differs from that of healthy
subjects and shows a low diversity (dysbiosis) [4–17]. Among the important factors that determine
the composition of gut microbiota are genetic factors, diet and drug intake, especially antibiotics [18].
Genetic factors explain only 5–10% of the intestinal bacterial composition [24]. Thus, environmental
factors appear to be of great importance in determining the intestinal bacterial profile [24,36]. Despite
the gene(s) responsible for IBS not being known yet, IBS seems to be hereditary [1,3] and this can at
least partially explain the abnormalities in intestinal microbiota. Moreover, IBS patients avoid certain
food items that they believe trigger their symptoms [37]. This might affect their intestinal bacterial
profile. Furthermore, proton pump inhibitors (PIPs) have been reported to affect the intestinal bacterial
composition [38]. In a recent study on a large cohort of IBS patients, 66% of the patients suffered from
gastro-oesophageal reflux, 97% had endoscopic-verified erosive oesophagitis, and most of the patients
used PIPs.
FMT appears to be effective at improving the symptoms and quality of life of patients with IBS,
and also at reducing their fatigue [18,20–22,25]. The apparent efficacy of frozen faeces facilitates the use
of FMT in the clinic by simplifying the logistical problems associated with FMT and makes it possible
to establish faeces banks [22,25,39]. The outcome of FMT is dependent on the donor, and utilising
a superdonor who is normobiotic and has a favourable specific bacterial signature is essential for
success, although what constitutes a “favourable” bacterial signature remains somewhat unclear [24].
We recently identified that such a signature should include an abundance of Streptococcus, Dorea,
and Lactobacillus spp. and bacteria belong to the Ruminococcaceae family. There are several issues that
need to be clarified before FMT can be applied routinely to IBS patients in the clinic, such as the route
of transplant administration, the transplant dose and whether the transplantation should involve a
single or repeated dose.
FMT can be achieved by administering the transplant to the duodenum via a nose catheter or the
working channel of a gastroscope, or to the colon via the working channel of a colonoscope or as an
enema [26]. It has been shown that administering the transplant to the duodenum is effective [20,25].
This makes FMT easier to perform in the clinic, since a gastroscopy takes a shorter time to perform
than a colonoscopy and does not require bowel preparation. Regarding the transplant dose needed for
a successful FMT, we have shown recently that the response rate is higher and the effect occurs earlier
and is more intense for a 60-g transplant than for a 30-g transplant.
The question addressed by the present study was whether the IBS patients who did not respond
to a 30-g transplant in our previous study would respond to a 60-g transplant. The present findings
showed that 70% of these patients responded to the FMT, and that increasing the dose of the transplant
and/or repeating FMT improved their abdominal symptoms, fatigue, quality of life and dysbiosis.
The present study showed further that increasing the dose of the transplant and/or repeating
FMT led to the complete remission of abdominal symptoms in 57% of the responders and to
clinically significant improvements in fatigue and quality of life in 80% and 67% of the patients,
respectively [27,31,33]. However, the present study had the following limitations: it investigated a
small cohort of patients and did not study the long-term effects of FMT. Furthermore, the patients
enrolled in the study adhered to a NICE-modified diet and therefore the outcomes cannot be extrapolated
to the whole IBS population.
5. Conclusions
FMT is an effective treatment for patients with IBS. The success of FMT with frozen faeces
administered via the upper gastrointestinal tract makes this treatment easy to perform in everyday
clinical work. However, the availability of a superdonor and high-dose and/or repeating FMT
are required.
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